Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07115667
What this trial is testing

Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

Who this might be right for
Solitary Bone PlasmacytomaPlasmacytoma of BonePlasma Cell Disorders
Institute of Hematology & Blood Diseases Hospital, China 21
Testing effectiveness (Phase 2)Ended earlyNCT04444141
What this trial is testing

PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T-cell Lymphoma
Akeso 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07789522
What this trial is testing

Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China 15
Early research (Phase 1)Study completedNCT05788484
What this trial is testing

CDX-585 in Patients With Advanced Malignancies

Who this might be right for
Non-small Cell Lung CancerGastric CancerHead and Neck Cancer+11 more
Celldex Therapeutics 20
Not applicableLooking for participantsNCT07352332
What this trial is testing

Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE

Who this might be right for
Childhood-onset Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine 6
Testing effectiveness (Phase 2)UnknownNCT05102214
What this trial is testing

HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid TumorsNon-small Cell Lung Cancer
Shanghai Henlius Biotech 150
Testing effectiveness (Phase 2)UnknownNCT05816499
What this trial is testing

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
NSCLC Stage IVNSCLC Stage IIIBNSCLC Stage IIIC
Shanghai Chest Hospital 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06196814
What this trial is testing

AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC

Who this might be right for
Efficacy
Hunan Province Tumor Hospital 150
Early research (Phase 1)Ended earlyNCT05908396
What this trial is testing

Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
IGM Biosciences, Inc. 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT04649359
What this trial is testing

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Who this might be right for
Multiple Myeloma
Pfizer 187
Large-scale testing (Phase 3)Looking for participantsNCT06932562
What this trial is testing

Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 1,000
Not applicableStudy completedNCT06359067
What this trial is testing

A Real-World Study of Bispecific Antibodies in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Assistance Publique - Hôpitaux de Paris 600
Not applicableStudy completedNCT06415656
What this trial is testing

VitalTraq for the Detection of CRS

Who this might be right for
Hematologic Malignancy
Duke University 32
Testing effectiveness (Phase 2)Study completedNCT04220307
What this trial is testing

A PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma
Akeso 34
Early research (Phase 1)Not Yet RecruitingNCT06134531
What this trial is testing

First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Nanfang Hospital, Southern Medical University 31
Testing effectiveness (Phase 2)Looking for participantsNCT06893783
What this trial is testing

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Who this might be right for
Neuroendocrine Carcinomas (NEC)Neuroendocrine Carcinoma of PancreasNeuroendocrine Carcinoma of Prostate
Inkeun Park 60
Early research (Phase 1)Active Not RecruitingNCT03530397
What this trial is testing

Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Who this might be right for
Selected Advanced Solid Tumors
MedImmune LLC 400
Testing effectiveness (Phase 2)Looking for participantsNCT05918445
What this trial is testing

PM8002 in the Treatment of Patients With Advanced Solid Tumors

Who this might be right for
Malignant Neoplasm
Biotheus Inc. 380
Early research (Phase 1)Looking for participantsNCT07343986
What this trial is testing

Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma

Who this might be right for
Glioblastoma (GBM)
University of Virginia 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515469
What this trial is testing

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC - Hepatocellular CarcinomaIparomlimab and Tuvonralimab InjectionNeoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and Hospital 30
Next Page